NeuroSearch A/S

NEUR 
(NasdaqOMXC) 
 
dkk 4.85
Updated 15:59:58
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 10,749
High DKK 4.91
Low DKK 4.80
Open DKK4.81
ISIN DK0010224666
Prev close DKK4.85
# of shares 24.55M
Market cap 119.09M DKK
Intraday

Market closed
NeuroSearch A/S
Market is closed, opens at 08:00
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  4.85 0.0% Stock price unchanged 10.5% Stock price increasing 39.0% Stock price increasing 33.6% Stock price increasing 30.0% Stock price increasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2016
0
-6,300
22,815
71,383
79,421
2015
0
-6,488
-5,538
72,400
78,594
2014
0
-13
-8
78
84
2013
29
-10
12
88
92
2012
121
-290
-276
81
208
2011
0
-383
-678
321
841
2010
69
-328
-259
994
1,392
2009
85
-356
-287
1,174
0
2008
67
-366
-382
0
0
2007
115
-253
-268
1,121
0
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Vivus Inc 0.47 1.5% Stock price increasing -1.8% Stock price decreasing -27.7% Stock price decreasing -51.7% Stock price decreasing -57.7% Stock price decreasing -6.5% Stock price decreasing
 
H Lundbeck A/S 323.10 1.0% Stock price increasing 2.9% Stock price increasing -8.3% Stock price decreasing -17.8% Stock price decreasing 9.1% Stock price increasing 2.6% Stock price increasing

Company profile

NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.

Peers

Instruments Last Change  
Vivus Inc 0.470 3.7% Stock price increasing
24,37,0,11,37,100,99,88,71,70
Lundbeck A/S 323.10 -1.0% Stock price decreasing
54,22,27,33,29,20,22,26,32,32

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2018 16:33:29
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180222.1 - EUROWEB7 - 2018-02-22 17:33:29 - 2018-02-22 16:33:29 - 1000 - Website: OKAY